Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-25T04:15:56.540Z Has data issue: false hasContentIssue false
  • English
  • Français

Vocal fold palsy following vinca alkaloid treatment

Published online by Cambridge University Press:  29 June 2007

B. V. Burns  and
J. C. Shotton
B. V. Burns*
Affiliation:
Department of Otolaryngology, Kent County Ophthalmic and Aural Hospital, Maidstone, Kent, UK
J. C. Shotton
Affiliation:
Department of Otolaryngology, Kent County Ophthalmic and Aural Hospital, Maidstone, Kent, UK
*
Address for correspondence: Dr B. V. Burns, M.B., Ch.B., Department of Otolaryngology, Kent County Ophthalmic and Aural Hospital, Church Street, Maidstone, Kent ME14 IDT
Get access Rights & Permissions [Opens in a new window]

Abstract

We report two patients with Hodgkin's disease on chemotherapy, one with vincristine, the other with vinblastine, who were referred to the ENT department with a vocal fold palsy. These drugs are commonly used in the treatment of haematological malignancies, and head and neck sarcomas. Examination showed a unilateral immobile fold. No causative local pathology was identified, and they were otherwise thought to be achieving remission, but the development of a fold palsy suggested a poor response to treatment. One patient's palsy resolved following completion of chemotherapy, but the other patient's persists, despite an otherwise good response to the treatment. The vinca alkaloids are neurotoxic, usually causing a peripheralneuropathy, but cranial mononeuropathies are a rare side-effect. A total of 27 previous cases of vocal fold palsy have been reported with the use of the vinca alkaloids, and such a lesion should not be assumed to be due to advancing lymphoma.

Keywords

Vinca alkaloids, complicationsVincristineVinblastineVocal fold palsy
Type
Clinical Records
Information
The Journal of Laryngology & Otology , Volume 112 , Issue 5 , May 1998 , pp. 485 - 487
Copyright
Copyright © JLO (1984) Limited 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Annino, D. J. Jr., MacArthur, C. J., Friedman, E. M. (1992) Vincristine induced recurrent laryngeal nerve paralysis. Laryngoscope 102(11): 1260–1262.CrossRefGoogle ScholarPubMed
Bohannon, R. A., Miller, D. G., Diamond, H. D. (1963) Vincristine in the treatment of lymphomas and leukaemias. Cancer Research 23: 613–621.Google Scholar
Bradley, W. B., Lassman, L. P., Pearce, G. W., Walton, J. N. (1970) The neuromyopathy of vincristine in man: clinical, electrophysiological and pathological studies. Journal of Neurological Science 10: 107–131.CrossRefGoogle ScholarPubMed
Brook, J., Schreiber, W. (1971) Vocal fold paralysis: a toxic reaction to vinblastine (NSC-49842) therapy. Cancer Chemotherapy Reports – Part 1. 55: 591–593.Google Scholar
Casey, E. B., Jellife, A. M., LeQuesne, P. M., Millet, Y. L. (1973) Vincristine neuropathy: clinical and electrophysiological changes. Brain 96: 69–86.CrossRefGoogle Scholar
Chisholm, R. C, Curry, S. B. (1978) Vincristine induced dysphagia. Southern Medical Journal 71(11): 1364–1365.CrossRefGoogle ScholarPubMed
Delaney, P. (1982) Vincristine-induced laryngeal nerve paralysis. Neurology 32(11): 1285–1288.CrossRefGoogle ScholarPubMed
Donaghy, M. J. (1996) Vincristine and neuropathies. Prescriber's Journal 36(2): 116–169.Google Scholar
Holland, J. F., Scharlau, C., Gailani, S., Krant, M. J., Olson, K. B., Horton, J., Shnider, B. I., Lynch, J. J., Owens, A., Carbone, P. P., Colsky, J., Grob, D., Miller, S. P., Hall, T. C. (1973) Vincristine treatment ofadvanced cancer: a cooperative study of 392 cases. Cancer Research 33: 1258–1264.Google Scholar
Lugassy, G., Shapira, A. (1990) Sensorineural hearing loss associated with vincristine treatment. Blut 61(5): 320–321.CrossRefGoogle ScholarPubMed
Mahajan, S. L., Ikeda, Y., Myers, T. J., Baldini, M. G. (1981) Acute acoustic nerve palsy associated with vincristine therapy. Cancer 47(10): 2404–2406.3.0.CO;2-2>CrossRefGoogle ScholarPubMed
McCarthy, G. M., Skillings, J. R. (1991) A prospective cohort study of the orofacial effects of vincristineneurotoxicity. Journal of Oral Pathology and Medicine 20(7): 345–349.CrossRefGoogle Scholar
McCarthy, G. M., Skillings, J. R. (1992) Jaw and other orofacial pain in patients receiving vincristine forthe treatment of cancer. Oral Surgery, Oral Medicine, Oral Pathology 74(3): 299–304.CrossRefGoogle Scholar
Postma, T. J., Benard, B. A., Huijgens, P. C., Ossenkoppele, G. J., Heimans, J. J. (1993) Long-term effects of vincristine on the peripheral nervous system. Journal of Neuro-Oncology 15(1):23–27.CrossRefGoogle ScholarPubMed
Ripps, H., Carr, R. E., Siegel, I. M., Greenstein, V. C. (1984) Functional abnormalities invincristine-induced night blindness. Investigative Ophthalmology and Visual Science 25(7): 787–794.Google ScholarPubMed
Rosenthal, S., Kaufman, S. (1974) Vincristine neurotoxicity. Annals of Internal Medicine 80: 333–373.CrossRefGoogle ScholarPubMed
Teichmann, K. D., Dabbagh, N. (1988) Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma. Journal of Ocular Pharmacology 4(2): 117–121.CrossRefGoogle Scholar
Tobias, J. D., Bozeman, P. M. (1991) Vincristine-induced recurrent laryngeal nerve paralysis in children. Intensive Care Medicine 17(5): 304–305.CrossRefGoogle ScholarPubMed
Whittaker, J. A., Griffith, I. P. (1977) Recurrent laryngeal nerve paralysis in patients receiving vincristine and vinblastine. British Medical Journal 1: 1251–1252.CrossRefGoogle ScholarPubMed
Wisniewski, H., Shelanski, M. L., Terry, R. D. (1968) Effects of mitotic spindle inhibitors on neurotubules and neurofilaments in anterior horn cells. Journal of Cell Biology 38: 224–229.CrossRefGoogle ScholarPubMed